Association of hemoglobin A1c variability and the incidence of heart failure with preserved ejection fraction in patients with type 2 diabetes mellitus and arterial hypertension

Hellenic Journal of Cardiology

Volumn 59, Issue 2, 2018, Pages 91-97

  Gu, Jun ^a   Fan, Yu Qi ^a   Zhang, Jun Feng ^a   Wang, Chang Qian ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

diastolic function; heart failure with preserved ejection fraction; hemoglobin A1c variability; hypertension; type 2 diabetes mellitus

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; SULFONYLUREA; GLYCOSYLATED HEMOGLOBIN;

ADULT; AGED; ARTICLE; ATRIAL FIBRILLATION; BODY MASS; COHORT ANALYSIS; DATA ANALYSIS; DIASTOLIC BLOOD PRESSURE; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; FOLLOW UP; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERTENSION; INTERVENTRICULAR SEPTUM; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; RETROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE; TISSUE DOPPLER IMAGING; TRANSTHORACIC ECHOCARDIOGRAPHY; BLOOD; CHINA; COMPLICATION; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; INCIDENCE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

AGED; CHINA; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; GLYCATED HEMOGLOBIN A; HEART FAILURE; HUMANS; HYPERTENSION; INCIDENCE; MALE; RETROSPECTIVE STUDIES; STROKE VOLUME; VENTRICULAR FUNCTION, LEFT;

EID: 85045013446     PISSN: 11099666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hjc.2017.08.001     Document Type: Article

References (29)

1. Yancy, C.W., Jessup, M., Bozkurt, B., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 62 (2013), e147–e239.
2. Ul Haq, M.A., Wong, C., Hare, D.L., Heart failure with preserved ejection fraction: an insight into its prevalence, predictors, and implications of early detection. Rev Cardiovasc Med 16 (2015), 20–27.
3. Dhingra, A., Garg, A., Kaur, S., et al. Epidemiology of heart failure with preserved ejection fraction. Curr Heart Fail Rep 11 (2014), 354–365.
4. Meng, X.Y., Zhou, Y., Zhang, J., et al. The association and interaction analysis of hypertension and diabetes mellitus on diastolic heart failure in a high-risk population. Int J Clin Exp Med 8 (2015), 21311–21318.
5. Gu, J., Fan, Y.Q., Bian, L., et al. Long-term prescription of beta-blocker delays the progression of heart failure with preserved ejection fraction in patients with hypertension: A retrospective observational cohort study. Eur J Prev Cardiol 23 (2016), 1421–1428.
6. Gu, J., Fan, Y.Q., Han, Z.H., et al. Association between long-term prescription of aldosterone antagonist and the progression of heart failure with preserved ejection fraction in hypertensive patients. Int J Cardiol 220 (2016), 56–60.
7. Yang, H.K., Kang, B., Lee, S.H., et al. Association between hemoglobin A1c variability and subclinical coronary atherosclerosis in subjects with type 2 diabetes. J Diabetes Complications 29 (2015), 776–782.
8. Wan, E.Y., Fung, C.S., Fong, D.Y., et al. Association of variability in hemoglobin A1c with cardiovascular diseases and mortality in Chinese patients with type 2 diabetes mellitus – A retrospective population-based cohort study. J Diabetes Complications 30 (2016), 1240–1247.
9. Takao, T., Matsuyama, Y., Yanagisawa, H., et al. Association between HbA1c variability and mortality in patients with type 2 diabetes. J Diabetes Complications 28 (2014), 494–499.
10. Bando, Y.K., Murohara, T., Diabetes-related heart failure. Circ J 78 (2014), 576–583.
11. Ruilope, L.M., Schmieder, R.E., Left ventricular hypertrophy and clinical outcomes in hypertensive patients. Am J Hypertens 21 (2008), 500–508.
12. Kattel, S., Memon, S., Saito, K., et al. An effect of left ventricular hypertrophy on mild-to-moderate left ventricular diastolic dysfunction. Hellenic J Cardiol 57 (2016), 92–98.
13. Aggeli, C., Tsiamis, E., Tousoulis, D., Left ventricular diastolic dysfunction: an old, known entity in a technologically modern era. Hellenic J Cardiol 57 (2016), 99–100.
14. Okada, R., Okada, A., Okada, T., et al. Visit-to-visit blood pressure variability is a marker of cardiac diastolic function and carotid atherosclerosis. BMC Cardiovasc Disord, 14, 2014, 188.
15. Al-Dorzi, H.M., Tamim, H.M., Arabi, Y.M., Glycaemic fluctuation predicts mortality in critically ill patients. Anaesth Intensive Care 38 (2010), 695–702.
16. Kuroda, M., Shinke, T., Otake, H., et al. Effects of daily glucose fluctuations on the healing response to everolimus-eluting stent implantation as assessed using continuous glucose monitoring and optical coherence tomography. Cardiovasc Diabetol, 15, 2016, 79.
17. Penno, G., Solini, A., Zoppini, G., et al. Hemoglobin A1c variability as an independent correlate of cardiovascular disease in patients with type 2 diabetes: a cross-sectional analysis of the renal insufficiency and cardiovascular events (RIACE) Italian multicenter study. Cardiovasc Diabetol, 12, 2013, 98.
18. Luk, A.O., Ma, R.C., Lau, E.S., et al. Risk association of HbA1c variability with chronic kidney disease and cardiovascular disease in type 2 diabetes: prospective analysis of the Hong Kong Diabetes Registry. Diabetes Metab Res Rev 29 (2013), 384–390.
19. Lee, E.J., Kim, Y.J., Kim, T.N., et al. A1c variability can predict coronary artery disease in patients with type 2 diabetes with mean a1c levels greater than 7. Endocrinol Metab (Seoul) 28 (2013), 125–132.
20. Keating, S.T., El-Osta, A., Glycemic memories and the epigenetic component of diabetic nephropathy. Curr Diab Rep 13 (2013), 574–581.
21. Monnier, L., Mas, E., Ginet, C., et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 295 (2006), 1681–1687.
22. Sun, L.Q., Chen, Y.Y., Wang, X., et al. The protective effect of alpha lipoic acid on Schwann cells exposed to constant or intermittent high glucose. Biochem Pharmacol 84 (2012), 961–973.
23. Maeda, M., Hayashi, T., Mizuno, N., et al. Intermittent high glucose implements stress-induced senescence in human vascular endothelial cells: role of superoxide production by NADPH oxidase. PLoS One, 10, 2015, e0123169.
24. Muggeo, M., Zoppini, G., Bonora, E., et al. Fasting plasma glucose variability predicts 10-year survival of type 2 diabetic patients: the Verona Diabetes Study. Diabetes Care 23 (2000), 45–50.
25. Cheng, D., Fei, Y., Liu, Y., et al. HbA1c variability and the risk of renal status progression in diabetes mellitus: a meta-analysis. PLoS One, 9, 2014, e115509.
26. Chiasson, J.L., Josse, R.G., Gomis, R., et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 290 (2003), 486–494.
27. Zinman, B., Wanner, C., Lachin, J.M., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
28. Rosenstock, J., Hansen, L., Zee, P., et al. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. Diabetes Care 38 (2015), 376–383.
29. Ponikowski, P., Voors, A.A., Anker, S.D., et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 18 (2016), 891–975.